• QIAGEN delivers on full-year 2018 outlook
  • FY 2018: Achieved 6% CER net sales growth to $1.5 billion vs.
    ~6-7% CER outlook and adj. diluted EPS of $1.34 ($1.35 CER vs.
    ~$1.33-1.34 CER outlook)
  • FY 2018: Adj. operating income margin rises to 27% of sales
    from 26% in 2017 and operating cash flow rises 25% to $359.5
    million
  • Q4 2018: Net sales of $403.2 million +2%, +5% CER vs. ~6-7% CER
    outlook; diluted EPS of $0.26; adj. EPS $0.40 ($0.41 CER vs.
    ~$0.39-0.40 CER outlook)
• Delivering 2018 growth from dynamic and disruptive Sample to
  Insight portfolio
  • QuantiFERON-TB delivers 21% CER full-year growth
  • Next-generation sequencing solution sales exceed 2018 target of
    $140 million
  • QIAsymphony tops full-year target of 2,300 cumulative placements
  • >300 placements of QIAstat-Dx multiplex syndromic testing
    platform in Europe
  • First European placements of NeuMoDx fully integrated PCR
    systems
• QIAGEN sets 2019 outlook for further growth in net sales and
  adjusted EPS

VENLO, the Netherlands–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24QGEN&src=ctag” target=”_blank”gt;$QGENlt;/agt;–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced
results of operations for the fourth quarter and full-year 2018, meeting
the goal for full-year net sales and exceeding the goal for adjusted
earnings per share while driving global expansion of its Sample to
Insight portfolio of molecular testing solutions.

“We are pleased with the achievements of QIAGEN in 2018, delivering a
performance in line with our outlook for net sales growth and exceeding
our target for adjusted earnings per share. Our teams made outstanding
progress on creating what we believe is one of the most dynamic and
disruptive portfolios of Sample to Insight solutions for molecular
testing,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
“Although we exceeded our target for adjusted diluted EPS, sales for the
fourth quarter were softer, due mainly to changes agreed upon during the
quarter in a third-party R&D project in Applied Testing linked to the
divestment of the veterinary testing assay portfolio and our decision to
accelerate the reduction of low-margin, third-party instrument service
contracts to ensure service capacity for several new QIAGEN instrument
systems, such as QIAstat-Dx and NeuMoDx.”

Please find the full press release here.

Contacts

John Gilardi
Vice President Corporate Communications and Investor
Relations
+49 2103 29 11711 and +1 240 686 2222
John.gilardi@qiagen.com

Dr. Sarah Fakih
Director Investor Relations
+49 2103 29 11457
Sarah.fakih@qiagen.com

Dr. Thomas Theuringer
Senior Director Public Relations and Digital
Communications
+49 2103 29 11826 and +1 240 686 7425
Thomas.theuringer@qiagen.com